Effects of Sacubactril Valsartan on Levels of AngⅡ,ALD,NT-proBNP and Cardiac Function in Patients with Chronic Heart Failure
Objective:To investigate the effect of Sacubitril Valsartan on the levels of angiotensin Ⅱ(AngⅡ),aldosterone(ALD)and N-terminal pro-B-type natriuretic peptide(NT-proBNP)and cardiac function in patients with chronic heart failure(CHF).Method:Sixty-five patients with CHF treated in the Third People's Hospital of Jingzhou from January 2021 to January 2023 were selected as the study objects.They were divided into control group(32 cases)and observation group(33 cases)according to random drawing method.The control group was given Valsartan Tablets,and the observation group was given Sarcubatril Valsartan Sodium Tablets.Laboratory indexes,quality of life and cardiac function were compared between the two groups before treatment and 6 months after treatment.Result:After 6 months of treatment,the levels of AngⅡ,ALD and NT-proBNP in both groups were decreased,and the levels of AngⅡ,ALD and NT-proBNP in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After 6 months of treatment,left ventricular ejection fraction(LVEF)increased,and left ventricular systolic diameter(LVESD)and left ventricular diastolic diameter(LVEDD)decreased in both groups.LVEF in observation group was significantly higher than that in control group,while LVESD and LVEDD were significantly lower than those in control group,the differences were statistically significant(P<0.05).After 6 months of treatment,the physical,emotional and other scores of both groups decreased,and the physical,emotional and other scores of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).Conclusion:In the treatment of CHF patients,Sacubactril Valsartan can reduce the levels of AngⅡ,ALD and NT-proBNP,reduce cardiac load,improve cardiac function and promote the improvement of quality of life.
国家科技期刊平台
NSTL
万方数据
维普
